Arch Therapeutics Announces Plans for Upcoming Activities

Arch Therapeutics Announces Plans for Upcoming Activities 
CAMBRIDGE, MA -- (Marketwired) -- 08/06/13 --  Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to provide a brief review of
proposed future activities. 
Arch Therapeutics CEO Dr. Terrence Norchi states, "We are thrilled to
be moving ahead with the development of our core technology. We
envision the potential future customers in the marketplace for
AC5(TM) and related products will include surgeons and other doctors,
government agencies, hospital and operating room management,
ambulances and trauma specialists. These market segments, even taken
separately, present meaningful opportunities for the Company." 
According to a 2012 report produced by MedMarket Diligence, LLC,
approximately 114 million surgical and procedure-based wounds occur
annually worldwide, including 36 million from surgery in the U.S. We
estimate that 20-25% of those surgeries are performed
laparoscopically. Additionally, there are many minor procedures and
operations that may not be included in those figures. Those surgeries
and other procedures could benefit from sealants and hemostatic
agents, as surgical and trauma patients are at significant risk for
morbidity and mortality from bleeding and/or leaking body fluid.  
As a result of this demand, use of hemostatic agents and sealants is
increasing. According to MedMarket Diligence, the market for these
products achieved approximately $3.4 billion in 2010 worldwide sales
and is projected to reach $4.5 billion in 2013 and surpass $6.5
billion in 2017. Over two-thirds of those sales are for hemostats.
The growth rate for sealants is even higher than that for hemostats
due to a general lack of available products and potentially larger
unmet need. 
The results of early data from preclinical tests have shown that
AC5(TM) achieves hemostasis quickly and effectively. From a
commercialization perspective, improvements in relevant synthetic
manufacturing techniques in the past several years have reduced
complexity and decreased materials cost. Further, AC5 will be made of
naturally occurring ingredients that are not sourced from humans or
other animals, but do exist in humans in their natural state. This
type of ingredient is categorized as "generally recognized as safe,"
or "GRAS," by the U.S. Food and Drug Administration ("FDA"). Although
the FDA and other regulatory authorities or related bodies will
finally determine the classification of AC5(TM), the Company believes
it meets the criteria for a medical device.  
In furtherance of its stated long-term business goals, the Company
reiterated plans to focus on the following activities during the
remainder of calendar year 2013 and calendar year 2014: 


 
--  further developing and securing intellectual property rights; and
--  engaging a large scale manufacturing partner to produce cGMP product
    for clinical trials;
--  participating in EU and, subsequently, U.S. regulatory meetings;
--  preparing for initial clinical trials, including developing clinical
    trial protocols;
--  conducting formal biocompatibility studies;
--  commencing human clinical trials.

  
Company CEO Dr. Terrence Norchi further comments, "We believe that
AC5(TM) will meet increasing demands, with anticipated market entry
for use in laparoscopic, as well as open surgery. While open surgery
represents the more established market for hemostatic agents,
approximately one-quarter of surgeries are laparoscopic, and that
number is growing. Many of the hemostasis products currently
available do not possess certain features and handling
characteristics that are ideal for the laparoscopic setting. Further,
there seems to be increased pressure to perform more complex
surgeries at reduced costs, including conducting operations in less
expensive outpatient settings. We believe that the novel features and
differentiating characteristics of our technology platform, starting
with AC5(TM), will address the need for highly improved hemostatic
and sealant products."  
Additional details regarding Arch Therapeutics, Inc., its business,
agreements and related matters are filed as part of the Company's
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at
www.archtherapeutics.com.  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.